Company intelligence / Profile preview
Flavocure Biotech Inc.
- Ownership
- Private
- Development stage
- Other
Overview
Flavocure’s lead candidate Caflanone has received FDA Orphan Drug Designation for pancreatic cancer and entered Phase I clinical trials in combination with radiotherapy. Preclinical data show activity against key driver mutations in several cancers. Cresorol has also received Orphan Drug Designation for AML but remains at an earlier stage. The pipeline includes additional programs targeting glioblastoma and multiple myeloma, all based on novel small molecule approaches derived from natural products.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (notably non-cannabinoid small molecules derived from cannabis and other natural products)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Flavocure Biotech Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flavocure Biotech Inc..